• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

撤回：一类新型特定的 HSP90 小分子抑制剂在体外和体内均表现出对人类黑色素瘤细胞的抗肿瘤活性。

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.

机构信息

Pfizer Worldwide Research and Development, Oncology Research, 10724 Science Center Drive, San Diego, CA 92121, United States.

出版信息

Cancer Lett. 2011 Jan 1;300(1):30-9. doi: 10.1016/j.canlet.2010.09.002.

DOI:10.1016/j.canlet.2010.09.002
PMID:20926183
Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the Authors. Following an investigation by Pfizer, Figures 2, 5B and 5C appear to be duplications and hence the conclusions in the manuscript cannot be verified. The Authors apologize for this inconvenience.

摘要

本文已被撤回

请参阅爱思唯尔关于文章撤回的政策（http://www.elsevier.com/locate/withdrawalpolicy）。应 Pfizer 的要求，本文已被撤回。经过 Pfizer 的调查，图 2、5B 和 5C 似乎存在重复，因此无法验证手稿中的结论。作者对此造成的不便表示歉意。

相似文献

1
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.撤回：一类新型特定的 HSP90 小分子抑制剂在体外和体内均表现出对人类黑色素瘤细胞的抗肿瘤活性。
Cancer Lett. 2011 Jan 1;300(1):30-9. doi: 10.1016/j.canlet.2010.09.002.
2
Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.热休克蛋白 90 抑制剂 ganetespib 在黑色素瘤中的活性。
PLoS One. 2013;8(2):e56134. doi: 10.1371/journal.pone.0056134. Epub 2013 Feb 13.
3
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.17-AAG和17-DMAG通过下调野生型B-Raf表达的葡萄膜黑色素瘤细胞系中的B-Raf来抑制细胞增殖。
Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2348-56. doi: 10.1167/iovs.07-1305. Epub 2008 Feb 15.
4
Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.姜黄素对黑色素瘤细胞的抗增殖和促凋亡作用与IκB激酶和核因子κB活性的抑制有关，且独立于B-Raf/丝裂原活化/细胞外信号调节蛋白激酶途径和Akt途径。
Cancer. 2005 Aug 15;104(4):879-90. doi: 10.1002/cncr.21216.
5
RETRACTED: LncRNA GAS6-AS1 facilitates the progression of breast cancer by targeting the miR-324-3p/SETD1A axis to activate the PI3K/AKT pathway.撤回：LncRNA GAS6-AS1 通过靶向 miR-324-3p/SETD1A 轴激活 PI3K/AKT 通路促进乳腺癌的进展。
Eur J Cell Biol. 2020 Nov;99(8):151124. doi: 10.1016/j.ejcb.2020.151124. Epub 2020 Sep 16.
6
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.17-烯丙基氨基-17-去甲氧基格尔德霉素对霍奇金淋巴瘤细胞中热休克蛋白90功能的抑制作用可下调Akt激酶、使细胞外信号调节激酶去磷酸化，并诱导细胞周期停滞和细胞死亡。
Clin Cancer Res. 2006 Jan 15;12(2):584-90. doi: 10.1158/1078-0432.CCR-05-1194.
7
Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.ERK和Akt的重新激活赋予了突变型BRAF结肠癌细胞对HSP90抑制剂AUY922的抗性。
Oncotarget. 2016 Aug 2;7(31):49597-49610. doi: 10.18632/oncotarget.10414.
8
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.人眼葡萄膜黑色素瘤细胞中的 PI3K/Akt 和 mTOR/P70S6K 信号通路：与 B-Raf/ERK 的相互作用。
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9. doi: 10.1167/iovs.09-3974. Epub 2009 Aug 6.
9
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.LY3009120是一种泛RAF抑制剂，在BRAF和KRAS突变的结直肠癌临床前模型中具有显著的抗肿瘤活性。
Oncotarget. 2017 Feb 7;8(6):9251-9266. doi: 10.18632/oncotarget.14002.
10
RETRACTED: Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.撤回：硼替佐米对获得性抗表皮生长因子受体酪氨酸激酶抑制剂耐药的人癌细胞的抗肿瘤活性。
Lung Cancer. 2011 Mar;71(3):283-90. doi: 10.1016/j.lungcan.2010.06.005.

引用本文的文献

1
A palladium catalyzed asymmetric desymmetrization approach to enantioenriched 1,3-disubstituted isoindolines.一种用于对映体富集的1,3-二取代异吲哚啉的钯催化不对称去对称化方法。
Chem Sci. 2023 Sep 26;14(40):11267-11272. doi: 10.1039/d3sc03496h. eCollection 2023 Oct 18.
2
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside.BRAF激酶抑制剂在黑色素瘤治疗中的意义：从实验室到临床
Cancers (Basel). 2019 Sep 11;11(9):1342. doi: 10.3390/cancers11091342.
3
HSP90 inhibitor 17-DMAG effectively alleviated the progress of thoracic aortic dissection by suppressing smooth muscle cell phenotypic switch.
热休克蛋白90抑制剂17-DMAG通过抑制平滑肌细胞表型转换有效缓解胸主动脉夹层的进展。
Am J Transl Res. 2019 Jan 15;11(1):509-518. eCollection 2019.
4
Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.热休克蛋白90抑制剂可增强黑色素瘤上的抗原表达，并增加T细胞对肿瘤细胞的识别。
PLoS One. 2014 Dec 12;9(12):e114506. doi: 10.1371/journal.pone.0114506. eCollection 2014.
5
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.AT13387对热休克蛋白90（HSP90）的抑制作用延缓了黑色素瘤模型中对BRAF抑制剂耐药性的出现，并克服了对BRAF和MEK双重抑制的耐药性。
Mol Cancer Ther. 2014 Dec;13(12):2793-2804. doi: 10.1158/1535-7163.MCT-14-0452. Epub 2014 Oct 27.
6
Effect of a heat shock protein 90-specific inhibitor on the proliferation and apoptosis induced by VEGF-C in cervical cancer cells.热休克蛋白90特异性抑制剂对VEGF-C诱导的宫颈癌细胞增殖和凋亡的影响。
Exp Ther Med. 2014 Nov;8(5):1559-1564. doi: 10.3892/etm.2014.1930. Epub 2014 Aug 22.
7
Tumor control versus adverse events with targeted anticancer therapies.靶向抗癌治疗的肿瘤控制与不良反应。
Nat Rev Clin Oncol. 2011 Dec 20;9(2):98-109. doi: 10.1038/nrclinonc.2011.192.